

P: 734-429-9053 | F: 734-944-3934

968 E Michigan Ave | Saline, MI 48176

Mon - Fri: 9am-6pm | Sat: 9am-3pm | Sun: Closed

COMPOUNDED SUBLINGUAL SEMAGLUTIDE

PATIENT INFORMATION

PRESCRIBER INFORMATION

Name:	Name:	
DOB:	NPI:	
Address:	Address:	
Phone:	Phone:	
Allergies:	Fax:	

PRESCRIPTION (SELECT ONE)

_____ **13-Week Protocol for GLP-1 Naive Patients**: This protocol is based on patient feedback and response to get patients to an effective maintenance dose efficiently.

Weeks 1-5: Semaglutide 2mg/ml: 0.5ml (1mg) daily for 2 weeks and increase to 1ml (2mg) daily Assess efficacy for patient and increase if needed

Weeks 6-9: Semaglutide 3mg/ml: take 1ml (3mg) daily Assess efficacy for patient and increase if needed

Weeks 10-13: Semaglutide 5mg/ml: take 1ml (5mg) daily Assess efficacy for patient and increase if needed

_____ Once daily, place 1ml under tongue for a minimum of 2 minutes before swallowing. Do not eat or drink for 30 minutes after dose.

Note: Patients who have been on a GLP-1 recently will need a higher dose to start than GLP-1 naive patients. Recommended starting dose is 3mg - 5mg daily depending on previous dosage.

SIG: Co	ompounded Sem	aglutide in Sub	Magna™ HMW	suspension (Select o	ne)	
	2mg/m	l	_ 3mg/ml	5mg/ml	7	mg/ml
	Qty (in 30ml inc	rements):				
	- 611					
	Refill	_ times				

Prescriber's Signature: _____

Date:

This fax transmission may contain confidential information belonging to the sender, which is greatly privileged. This information is intended for the use of the recipient named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or taking of any action in reliance on the contents of this faxed information is strictly prohibited. Please notify us by phone to arrange for the return of the original documents. No claims are made as to the safety, efficacy or quality of these formulations.